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Purpose
The purpose of this prospective observational study was to determine the incidence, patterns,
and predisposing factors for brain tumor-related epilepsy (BTRE) during chemotherapy for
systemic cancer with single brain metastasis (BM). 
Materials and Methods
Between February 2006 and June 2010, 103 patients who underwent chemotherapy for
systemic cancer with single BM were enrolled. We compared the clinical factors of patients
and BM between patients with and without BTRE. We determined the number of patients
with BTRE attacks, and seizure-free survival according to the following comparative groups:
presence vs. absence of a history of BTRE; high-risk vs. low-risk groups; and presence vs.
absence of disease-progression of BM.
Results
Ninety-three of 103 patients (90.3%) remained seizure-free during chemotherapy. The
seizure-free rates were 88.9% and 91.0% among patients with or without a history of BTRE,
respectively (p=0.694), 87.8%and 92.6%among high- and low-risk patients (p=0.427), respec-
tively, and 62.5%and 98.7%among patients with or without disease-progression of BM (p=0.001),
retrospectively. Based on multivariate analysis, the significance of abnormal findings on
electroencephalogram (EEG) (p=0.017), and the absence of disease-progression of BM (p=0.001)
had an association with seizure-free survival.
Conclusion
The significance of abnormal findings on EEG, and disease-progression of BM play important
roles in the development of BTRE during chemotherapy for systemic cancer with BM.
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Introduction
The incidence of brain tumors among those with epilepsy is
approximately 4% [1]. Conversely, the frequency of epilepsy is 30%
among patients with brain tumors, although this depends on the
tumor type [2]. In 30-50% of patients with brain tumors, epileptic
seizures are the presenting symptom, and an additional 10-30% of
patients will develop seizures later during the course of the disease
[1,3,4]. Furthermore, epilepsy has been reported inĥ80% of
patients with low-grade gliomas (World Health Organization grade
2) [5], 30-60% of patients with high-grade gliomas [6], up to 40% of
patients with meningiomas [7], and approximately 20% of patients
with primary central nervous system lymphomas [8]. In fact,
approximately 25% of patients with brain metastases (BMs) have
seizures and 10% of those patients complain of seizures as the
presenting symptom [3,9].
Brain tumor-related epilepsy (BTRE), especially in systemic cancer
patients, has a significant impact on the quality of life. BTRE
interferes with driving and working, reduces independence, increases
anxiety, and generates depression [10]. Furthermore, BTRE are
often drug-resistant [11]. The resistance of patients with BTRE to
anti-epileptic drugs (AEDs) probably reflects different pathophy-
siologic mechanisms, such as those affecting peritumoral brainYoung Zoon Kim, et al_Brain Tumor-Related Epilepsy during Chemotherapy
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tissue morphology, pH, ion levels, and amino acid changes, and
different pharmacologic interactions [11]. Although the frequencies
of seizures can be effectively reduced by administrating AEDs, these
agents can create a host of new problems. For example, AEDs can
interact with corticosteroid metabolism [4,12], reduce the efficacies
of a variety of chemotherapeutic agents [13], and cause side effects
more frequently than epileptic patients without brain tumors [3].
During systemic chemotherapy, drug interactions are a primary
concern because the majority of chemotherapeutics have a narrow
therapeutic index. Therefore, careful and proactive planning is re-
quired to achieve adequate chemotherapeutic dosing without inducing
toxicity in patients with BTRE. Furthermore, chemotherapeutics can
also accelerate AED metabolism, and prevent seizure control during
chemotherapy.
However, some of the newer AEDs are not metabolized or meta-
bolized to a lesser degree by the cytochrome P450 isoenzyme, which
may substantially reduce the risks of drug interactions. However,
despite the more favorable pharmacokinetic profiles of recently
introduced AEDs, little clinical information is available regarding
the effects of these drugs in patients with brain tumors or concerning
potential interactions between these agents and many chemo-
therapeutics. Topiramate, one of the recently developed AEDs, is
interesting from a pharmacokinetic standpoint because topiramate
induces the cytochrome P450 isoenzyme only at low levels, and this
is associated with lower pharmacologic interactions [14]. 
In the present study during systemic chemotherapy of BM we
examined the incidence and patterns of BTRE, and compared the
clinical characteristics of patients and features of BM between
patients who did and did not have a BTRE. Additionally, we
investigated the predisposing factors for development of a BTRE in
BM patients, and analyzed the factors influencing seizure-free
survivals during systemic chemotherapy of BM.
Materials and Methods
1   Study population
This prospective observational study involved 103 patients who
were recruited between February 2006 and June 2010. All patients
underwent chemotherapy for systemic cancer with single BM and
concomitant topiramate as an AED at our institute, and met the
following inclusion criteria: 1) ageĥ20 years; 2) diagnosis made by
surgical intervention or magnetic resonance imaging (MRI) of the
brain; 3) abnormal electroencephalographic findings; 4) BM located
in the supratentorial area; and 5) single BM. Patients with a history
of prolonged seizures before the diagnosis of BM, a history of medi-
cally-intractable seizures, contraindication to topiramate admini-
stration (such as, a renal stone or dementia, or systemic chemo-
therapy), or a normal finding on electroencephalogram (EEG)
without seizures before chemotherapy were excluded. A radiologic
review was undertaken to diagnose a single BM by two neuro-
radiologists (S.Y.G. and L.H.Y.). Single BM was defined as one
metastatic lesion to the brain without considering extracranial
metastases. A MRI was performed using a 1.5 T clinical scanner
(Signa Horizon, GE Healthcare, Milwaukee, WI). 
The purpose of the study was explained to patients and their
families prior to enrollment. The local ethical committee at our
institute approved the study protocol (MSH-2006-010).
2   Initial treatment of brain metastasis
Surgical resection was considered in the following conditions: 1)
new onset of neurological deficits; 2) large mass with mass effect or
severe peritumoral edema; 3) presence of tumor bleeding; 4) presence
of increased intracranial pressure; and 5) surgically accessible
location. Radiotherapy was considered in patients with deeply-
located BM which led to the new onset of neurologic symptoms. In
patients with a BM of small size and no neurologic symptoms, we
started systemic chemotherapy for primary cancer.
3   Evaluation before chemotherapy
Adequate hematologic, renal, and hepatic functions were deter-
mined using blood samples and defined as follows: absolute granu-
locyte count,ĥ1,500/dL; white blood cell count,ĥ4,000/dL; platelet
count,ĥ100,000/dL; total bilirubin level,ģ1.8 mg/dL; transaminase
level,ģ2.5 times the upper limit of normal; and creatinine concen-
tration,60 mL/m
2/1.73.
Patients scheduled to undergo chemotherapy for systemic cancer
with single BM underwent EEG. EEG was performed using gold
cup electrodes directly applied to the scalp, and located according to
the international 10-20 system. Skin impedance was maintained at
ģ5 KΩ. Outputs were recorded from the following locations: left
and right frontal-mastoid (FP1-A1 and FP2-A2 [channels 1 and 2]),
left and right frontal-CZ (FP1-CZ and FP2-CZ [channels 3 and 4]),
plus a ground electrode placed at the center of the forehead. EEGs
were recorded using a portable Aspect A-1000 EEG monitor (Aspect
Medical System, Inc., Natick, MA). The importance of EEG
abnormalities was categorized according to severity and specificity:
significance I abnormality, intermittent generalized slowing; signifi-
cance II abnormality, intermittent regional slowing; and significance
III abnormality, spike waves or continuous generalized or regional
slowing [15]. The higher the level of significance of the EEG
abnormality, the more frequent seizures occur.
The presence of cognitive impairment was determined before
every cycle using the Mini-Mental State Examination (MMSE),
which involves repeating lists of words, arithmetic, language use
and comprehension, and basic motor skills [16]. 
Functional status was determined using the Karnofsky Perfor-
mance Scale (KPS) according to which patients with a score70Cancer Res Treat. 2011;43(3):160-169
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are deemed to be capable of self-care, and patients with a score ģ70
are considered to require assistance to conduct the activities of daily
life [17].
4   Evaluation during systemic chemotherapy
Blood samples, MMSE, and KPS were checked before every
cycle in patients who underwent cyclic chemotherapy, whereas
examinations were performed monthly in patients on continuous
chemotherapy.
When a seizure occurred, we attempted to perform brain computed
tomography scans and obtained blood samples in order to determine
the metabolic origin of the seizure. Seizure type, frequency, time of
the attack, and the total number of seizures were documented.
Seizure types were defined according to the scheme proposed by the
International League against Epilepsy in 1981 [18]. Data concerning
seizures, such as auras, ictal patterns, ictal duration, postictal
amnesia, and postictal neurologic sequelae, were gathered from the
clinical notes which were recorded by the patients or family members.
The frequency of seizures during chemotherapy was calculated by
summing seizures from the start of chemotherapy to the completion
of chemotherapy.
The severity of side effects produced by topiramate was evaluated
using the “Common Terminology Criteria for Adverse Events
(CTCAE)” [19]. Topiramate was switched to another AED at grade
4 toxicity.
5   AED application and titration
If an abnormal signal was observed by EEG, even in patients who
did not have a history of BTRE, topiramate was started at 50
mg/day 2 weeks before chemotherapy. In patients who were already
taking another AED, AEDs were switched to topiramate at an initial
dose of 50 mg/day 2 weeks before chemotherapy. Topiramate was
increased to 100 mg/day at the start of chemotherapy. Thereafter,
topiramate was adjusted according to response using weekly in-
crements of 25 mg/day to a maximum allowable dose of 400 mg/day.
When seizures occurred, add-on AEDs, such as levetiracetam, were
considered. During follow-up, blood samples were collected monthly
for hematotoxicity evaluation. All patients enrolled in this study
underwent chemotherapy for systemic cancer with single BM and
concomitant topiramate for3 months.
6   Analyses of BTRE
We analyzed the total number of seizures, seizure-free rates, and
seizure-free survival during chemotherapy. One hundred three patients
were examined for BTRE patterns. In additionally, we compared
BTRE patterns in the following subgroups: 1) patients who did and
did not have a history of seizures before chemotherapy; 2) patients
with or without a BTRE risk factor; and 3) patients with or without
disease-progression of BM.    
Risk factors of BTRE were taken from the review by Beaumont
and Whittle [20]. The following locations have the lowest BTRE
thresholds: limbic and temporal lobe; the perirolandic primary motor
and primary somatic sensory cortices; the frontal parasagittal region
of the supplementary motor area; and the opercula and insula regions
of the secondary somatic sensory areas. Therefore, we classified
patients with BM which was located in an area of the lowest BTRE
threshold as “high risk;” all other patients were categorized as “low
risk.”
Disease-progression of BM was defined as follows: 1) in the case
of surgical resection for BM, the appearance of a new enhancing
lesion at a remote or original site from the brain tumor bed, or at
least a 25% increase in the product of the two largest perpendicular
diameters of the residual BM; 2) in the case of radiotherapy or front
systemic chemotherapy for BM, the appearance of a new enhancing
lesion at a remote site from the original BM, or at least a 25% increase
in the product of the two largest perpendicular diameters of the
original BM.
7   Statistical analysis
Discrete variables were compared using a chi-square test or
Fisher’s exact test and continuous variables were compared using a
Student’s t-test. Seizure-free survival was determined using the
Kaplan-Meier method. The log-rank test and Cox regression analysis
was used to examine the association between the variables and
seizure-free survival. Univariate analysis was used to determine the
effects of age, gender, KPS score, significance of abnormal EEG
findings, previous history of seizures, histopathology of primary
cancer, location of brain tumor, therapeutic modality for primary
cancer, and disease-progression of BM. Variables that were signi-
ficantly associated with seizure-free survival based on univariate
analysis were subjected to multivariate analysis. Differences were
regarded significant when the probability values wereģ0.05.
Statistical analyses were performed using SPSS ver. 12.0 (SPSS
Inc., Chicago, IL).
Results 
Table 1 shows patient clinical characteristics before systemic
chemotherapy with concomitant topiramate and Table 2 illustrates
the characteristics of single brain metastasis. Between February
2006 and June 2010, 103 patients that met the inclusion criteria
constituted the study cohort. There were 64 men and 39 women
with an overall mean age of 60.8 years (range, 22 to 79 years). With
a median follow-up of 8.7 months (range, 3.2 to 15.8 months), 10
patients (9.7%) had BTRE attacks.Young Zoon Kim, et al_Brain Tumor-Related Epilepsy during Chemotherapy
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Total Patients with BTRE Patients without BTRE
p-value
(n=103) (n=10) (n=93)
Mean age (range, yr) 60.8 (22-79) 64.4 (37-79) 60.4 (22-76) 0.043
a)
Gender 0.137
b)
Male 64 (62.1) 7 (70.0) 57 (61.3)
Female 39 (37.9) 3 (30.0) 36 (38.7)
History of seizure 0.337
b)
Presence 36 (35.0) 4 (40.0) 32 (34.4)
Absence  67 (65.0) 6 (60.0) 61 (65.6)
KPS score 0.318
b)
100-90 68 (66.0) 6 (60.0) 62 (66.7)
80-70 27 (26.2) 2 (20.0) 25 (26.9)
60 8 (7.8) 2 (20.0) 6 (6.4)
Abnormality of EEG 0.019
b)
Significance I 53 (51.4) 3 (30.0) 50 (53.8)
Significance II 29 (28.2) 1 (10.0) 28 (30.1)
Significance III 21 (20.4) 6 (60.0) 15 (16.1)
Mean MMSE (range) 24.4 (12-30) 22.7 (12-30) 24.6 (17-30) 0.227
a)
Extracranial metastasis 0.108
b)
0 38 (36.9) 2 (20.0) 36 (38.7)
1 43 (41.7) 5 (50.0) 38 (36.9)
2 22 (21.4) 3 (30.0) 19 (18.4)
Table 1. Clinical characteristics of the patients (n=103)
Values are presented as number (%). BTRE, brain tumor related epilepsy; KPS, Karnofsky Performance Scale; EEG, electroencephalogram; MMSE, Mini-Mental State
Examination. 
a)Student’s t-test, 
b)Fisher’s exact test.
Total Patients with BTRE Patients without BTRE
p-value
a)
(n=103) (n=10) (n=93)
Histology of primary cancer ģ0.05
Non-small cell lung cancer 67 (65.1) 7 (70.0) 60 (64.5)
Small cell lung cancer 6 (5.8) 1 (10.0) 5 (5.4)
Renal cell carcinoma 9 (8.7) 1 (10.0) 8 (8.6)
Hepatocellular carcinoma 7 (6.8) 0 (0.0) 7 (7.5)
Colorectal cancer 5 (4.9) 0 (0.0) 5 (5.4)
Breast cancer 3 (2.9) 0 (0.0) 3 (3.2)
Others 6 (5.8) 1 (10.0) 5 (5.4)
Main location of tumors ģ0.05
Frontal lobe 24 (23.3) 2 (20.0) 22 (23.7)
Non-motor cortex 15 (14.6) 1 (10.0) 14 (15.1)
Motor cortex 9 (8.7) 1 (10.0) 8 (8.6)
Temporal and limbic lobe 31 (30.1) 4 (40.0) 27 (29.0)
Parietal lobe 16 (15.5) 2 (20.0) 14 (15.1)
Non-sensory cortex 7 (6.8) 1 (10.0) 6 (6.5)
Sensory cortex 9 (8.7) 1 (10.0) 8 (8.6)
Occipital lobe 3 (2.9) 0 (0.0) 3 (3.2)
Deep locations 29 (28.2) 2 (20.0) 27 (29.0)
Therapeutic modality ģ0.05
Radiosurgery 33 (32.0) 3 (30.0) 30 (32.3)
Fractionated stereotactic radiotherapy 4 (3.9) 0 (0.0) 4 (4.3)
Whole brain radiotherapy 5 (4.9) 1 (10.0) 4 (4.3)
Surgical resection 51 (49.5) 5 (50.0) 46 (49.5)
None 10 (9.7) 1 (10.0) 9 (9.6)
Table 2. Characteristics of single brain metastases (n=103)
Values are presented as number (%). BTRE, brain tumor related epilepsy. 
a)Fisher’s exact test.Cancer Res Treat. 2011;43(3):160-169
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The overall seizure-free rate was 90.3%. Thirty-six patients
(35.0%) had brain tumors associated with a history of seizures,
while 67 patients (65.0%) did not have brain tumors associated with
a history of seizures.
1   Previous history of BTRE: presence vs. absence
Thirty-six patients (35.0%) had a history of BTRE. No statistical
difference was observed between the two subgroups with respect to
age, gender, KPS score, and MMSE. However, by EEG those without
a history of BTRE had more significance I abnormalities (71.6% vs.
13.8%, pģ0.05). In contrast, patients with a history of BTRE had
more significance II or III abnormalities (86.2% vs. 28.4%, p
ģ0.05). Table 3 details clinical characteristics before systemic
chemotherapy according to a history of BTRE. 
Patients with a BTRE history had more BMs located in the motor
cortex of the frontal lobe (19.4% vs. 3.0%, pģ0.05) and in the
temporal limbic lobe (41.7% vs. 23.9%, pģ0.05) than those without
a BTRE history. In contrast, patients without a BTRE history had
more BMs located in the non-motor cortex of the frontal lobe and
deep brain (17.9% vs. 8.3%, pģ0.05). Table 4 summaries BM
features according to BTRE history.
In the log-rank test and Kaplan-Meier method, because the
seizure-free survival period in patients with or without a history of
BTRE did not reach the median value, we could not calculate the
median time to seizure attack, and no statistical difference was
detected (p=0.694). 
The median duration of follow-up duration was 9.2 months (range,
3.2 to 15.1 months) in patients with a history of BTRE and 8.6
months (range, 3.4 to 15.8 months) in patients without a history of
BTRE (pĥ0.05). Fig. 1 shows the seizure-free survival curve in the
two groups of patients.
2   Risk of BTRE: high- vs. low-risk
Forty-nine patients (47.6%) were included in the high-risk group
and 54 patients (52.4%) were in the low-risk group. These two
groups were similar in with respect to a BTRE history, and non-
significantly different in terms of age, gender, KPS score, and
MMSE. However, on EEG patients in the low-risk group had more
significance I abnormalities than patients in the high-risk group
(75.9% vs. 22.4%, pģ0.05). In contrast, patients in the high-risk
group had more significance II and III abnormalities (75.5% vs.
24.1%, pģ0.05). Table 3 details the clinical characteristics of
patients before systemic chemotherapy according to BTRE risk.
Differences were expected between these two risk groups in terms
of BM features because the group allocations were made using BM
features. With respect to therapeutic modality for BM, there was no
significant difference between the two groups (pĥ0.05). Table 4
summarizes brain tumor features according to BTRE risk.
Also, the seizure-free survival period in the two groups did not
reach a median value in the log-rank test. There was no statistical
Previous seizure history Risk group Disease-progression of BM
Absence Presence Low risk High risk Presence Absence
No. of patients 67 (65.0) 36 (35.0) 54 (52.4) 49 (47.6) 24 (23.3) 79 (76.7)
Mean age (range, yr) 62.1 (22-79) 58.4 (25-76) 60.4 (22-75) 61.2 (25-79) 64.8
a) (25-79) 59.6
a) (22-76)
Gender
Male 40 (59.7) 24 (66.7) 33 (61.1) 32 (65.3) 16 (66.7) 48 (60.8)
Female 27 (40.3) 12 (33.3) 21 (38.9) 17 (34.7) 8 (33.3) 31 (39.2)
KPS 
100-90 44 (65.7) 24 (66.7) 31 (57.4) 31 (63.3) 15 (62.5) 53 (67.1)
80-70 18 (26.9) 9 (25.0) 13 (24.1) 13 (26.5) 5 (20.8) 22 (27.8)
60 5 (7.5) 3 (8.3) 5 (9.3) 4 (8.2) 4 (16.7)
a) 4 (5.1)
a)
Abnormality of EEG
Significance I 48 (71.6)
a) 5 (13.8)
a) 41 (75.9)
a) 12 (22.4)
a) 11 (45.8) 42 (53.2)
Significance II 12 (18.0)
a) 17 (47.2)
a) 12 (22.2)
a) 19 (38.8)
a) 8 (33.3) 21 (26.6)
Significance III 7 (10.4)
a) 14 (38.9)
a) 1 (1.9)
a) 18 (36.7)
a) 5 (20.8) 16 (20.3)
Mean MMSE (range) 24.9 (15-30) 23.4 (12-30) 24.6 (15-30) 23.9 (12-30) 22.3 (12-30) 24.8 (17-30)
Extracranial metastasis
0 23 (34.3) 15 (41.7) 20 (37.0) 18 (36.7) 8 (33.3) 30 (40.0)
1 29 (43.3) 14 (38.9) 21 (38.9) 22 (44.9) 9 (37.5) 34 (43.0)
2 15 (22.4) 7 (19.4) 13 (24.1) 9 (18.4) 7 (29.2) 15 (19.0)
Table 3. Clinical characteristics of patients before systemic chemotherapy according to each comparative group (n=103)
Values are presented as number (%). BM, brain metastasis; KPS, Karnofsky performance scale; EEG, electroencephalogram; MMSE, Mini-Mental State Examination. 
a)Those
variables have statistically significant difference (pģ0.05).Young Zoon Kim, et al_Brain Tumor-Related Epilepsy during Chemotherapy
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difference in seizure-free survival between the two groups (p=0.427),
and Fig. 2 shows the Kaplan-Meier survival curve. The median
duration of follow-up was 8.8 months (range, 3.5 to 15.8 months) in
the high-risk group and 8.6 months (range, 3.2 to 14.7 months) in
the low-risk group (pĥ0.05).
3   Disease-progression of BM: presence vs. absence
Disease-progression occurred in 24 BMs (23.3%) and was not
detected in 79 BMs (76.7%). Patients with disease-progression were
older (64.8 years vs. 59.6 years, pģ0.05), and had a KPS score of
60 (16.7% vs. 5.1%, pģ0.05). Table 3 shows the clinical charac-
teristics of patients during systemic chemotherapy according to
disease-progression of BM.
Concerning an origin of BM, there was no statistical difference
between non-small cell lung cancer and other cancers (pĥ0.05).
Also, there was no significant difference in disease-progression of
BM after surgical resection or radiotherapy for BM (pĥ0.05). Table 4
summarizes the BM features with respect to disease-progression of BM.
Although the seizure-free survival period did not reach a median
value in the log-rank test, there was a significant statistical difference
between patients with and without disease-progression (p=0.001)
based on Kaplan-Meier analysis. In Fig. 3, the Kaplan-Meier survival
curve presents the difference. The median duration of follow-up was
8.4 months (range, 3.2 to 14.4 months) in patients with disease-
progression of BM and 8.9 months (range, 3.4 to 15.8 months) in
patients without disease-progression (pĥ0.05).
4   Results of Cox regression analysis for seizure-free
survival
Table 5 shows the results of regression analysis of each factor.
Three variables, including the significance of the EEG abnormality,
the risk for epileptogenesis according to the location of the BM, and
the disease-progression of BM, had a positive association with
seizure-free survival. Based on univariate analysis, the odds ratio of
significance of abnormality in EEG was 3.42 (95% confidence interval
[CI], 1.21 to 5.92; p=0.024) in I vs. III, and 2.63 (95% CI, 1.77 to
3.56; p=0.050) in II vs. III. After multivariate adjustment, the odds
ratio of the significance of the EEG abnormality was 3.46 (95% CI,
1.5 to 5.93; p=0.017) in I vs. III, and 2.71 (95% CI, 1.85 to 4.18,
p=0.048) in II vs. III. The odds ratio of risk for epileptogenesis was
2.46 (95% CI, 1.61 to 3.47, p=0.046) based on univariate analysis.
However, after multi-factor adjustment, the variable of risk for
epileptogensis did not have an association with seizure-free survival.
In terms of disease-progression of BM, the odds ratio was 4.41
(95% CI, 1.52 to 6.80; p=0.003) based on univariate analysis, and
4.63 (95% CI, 2.23 to 7.04; p=0.001) after multi-factor adjustment.
Seizure history Risk group Disease-progression of BM
Absence Presence Low risk High risk Presence Absence
No. of patients 67 (65.0) 36 (35.0) 54 (52.4) 49 (47.6) 24 (23.3) 79 (76.7)
Histology of primary cancer
Non-small cell lung cancer 42 (62.7) 25 (69.4) 36 (66.7) 31 (63.3) 17 (70.8) 50 (63.3)
Other cancer 25 (37.3) 11 (30.6) 18 (33.3) 18 (36.7) 7 (29.2) 29 (36.7)
Main location of tumors
Frontal lobe 14 (20.9) 10 (27.8) 15 (27.8) 9 (18.4) 5 (20.8) 19 (24.1)
Non-motor cortex 12 (17.9)
a) 3 (8.3)
a) 15 (27.8)
a) 0 (0.0)
a) 3 (12.5) 12 (15.2)
Motor cortex 2 (3.0)
a) 7 (19.4)
a) 0 (0.0)
a) 9 (18.4)
a) 2 (8.3) 7 (8.9)
Temporal and Limbic lobe 16 (23.9)
a) 15 (41.7)
a) 0 (0.0)
a) 31 (63.3)
a) 8 (33.3) 23 (29.1)
Parietal lobe 10 (15.0) 6 (16.7) 7 (13.0) 9 (18.4) 4 (16.7) 12 (15.2)
Non-sensory cortex 4 (6.0) 3 (8.3) 7 (13.0)
a) 0 (0.0)
a) 2 (8.3) 5 (6.3)
Sensory cortex 6 (9.0) 3 (8.3) 0 (0.0)
a) 9 (18.4)
a) 2 (8.3) 7 (8.9)
Occipital lobe 3 (4.5) 0 (0.0) 3 (5.6)
a) 0 (0.0)
a) 1 (4.2) 2 (2.5)
Deep locations 24 (35.8)
a) 5 (13.9)
a) 29 (53.7)
a) 0 (0.0)
a) 6 (25.0) 23 (29.1)
Surgical intervention
Radiosurgery 23 (34.3) 10 (27.8) 17 (29.8) 16 (32.7) 7 (29.2) 26 (32.9)
Fractionated stereotactic radiotherapy 3 (4.5) 1 (2.8) 2 (3.7) 2 (4.1) 0 (0.0) 4 (5.1)
Whole brain radiotherapy  3 (4.5) 2 (5.6) 2 (3.7) 3 (6.1) 1 (4.2) 4 (5.1)
Surgical resection 31 (46.3) 20 (55.5) 27 (50.0) 24 (49.0) 13 (54.2) 38 (48.1)
None 7 (10.4) 3 (8.3) 6 (11.1) 4 (8.2) 3 (12.5) 7 (8.9)
Table 4. Features of single brain metastases according to each comparative group (n=103)
Values are presented as number (%). BM, brain metastasis. 
a)Those variables have statistically significant difference (pģ0.05).Cancer Res Treat. 2011;43(3):160-169
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5 Patterns of BTRE during systemic chemotherapy for
BM
Table 6 shows the patterns of BTRE during systemic chemotherapy
for BM. The mean dose of topiramate was 183.4 mg/day (range,
100 to 400 mg/day). Ten patients (9.7%) suffered from BTRE
during systemic chemotherapy. Specifically, 2 patients experienced
one seizure, 4 patients had 2 seizures, and 4 patients had3
seizures. The first seizure occurred in 1 patient within 1 month of
chemotherapy, in 2 patients between 1 and 2 months, in 3 patients
between 2 and 4 months, and in 4 patients after 4 months. A total of
24 seizures occurred (3 partial seizures, 12 partial seizures with
evolving secondary generation, and 9 generalized tonic-clonic
seizures).
Six of 67 patients (9.0%) without a history of BTRE and four of
36 patients (11.1%) with a history of BTRE experienced seizure
attack while on topiramate, which was not statistically significant.
However, the number of seizures per patient in patients with or
without a BTRE history were 0.19 and 0.31, respectively, and this
difference was significant (p=0.024).   
Although new onset seizures occurred in six patients without a
BTRE history, 88.9% (32 of 36) of those with a previous BTRE
history achieved a seizure-free state on topiramate. Seizure-free rates
were similar in the low- and high-risk groups (92.6% and 87.8%,
respectively). Although seizures occurred in 7.4% (4 patients) in the
low-risk group and in 12.2% (6 patients) in the high-risk group, this
difference was not significant (p=0.283). Furthermore, no statistical
difference was observed between the two groups in terms of seizure
number per patient (0.20 vs. 0.26, p=0.202). 
In terms of disease-progression of BM, 9 (37.5%) patients with
disease-progression of BM experienced seizures and only 1 (1.3%)
patient without disease-progression of BM experienced a seizure
(p=0.000); the average number of seizures per patient was 0.96 for
patients with disease-progression of BM and only 0.01 in patients
without disease progression of BM (p=0.000). Furthermore, these
two differences were highly significant. 
Discussion
BTRE is difficult to control with AEDs, perhaps because of the
underlying pathophysiologic mechanisms and interactions with
other drugs [11]. These seizures may be extremely distressing for
patients, and are a major source of morbidity and diminished quality
of life in patients with brain tumors and other cancers [21]. For these
reasons, AEDs are administered for prophylaxis to brain tumor
patients during chemotherapy. In fact, a meta-analysis of 4 rando-
mized trials involving1 AED and 318 patients with a variety of
intracranial neoplasms showed that prophylaxis with phenytoin,
phenobarbital, or valproate is ineffective [10]. Furthermore, after
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adding patients from 8 non-randomized studies to the meta-analysis,
which raised the total to 1,100 patients; 24% were shown to have
side effects (mainly cognitive difficulties and rashes), which led to
treatment discontinuation. As a result, the American Academy of
Neurology recommends that prophylactic AEDs not be routinely
administered to patients with a newly diagnosed brain tumor, or
alternatively treatment be tapered off after the first post-operative
week [3]. Nevertheless, it is possible that certain subgroups of
patients could benefit from prophylaxis with newer AEDs, which
are purported to have fewer side effects. However, relatively few
studies have been performed on the use of these newer AEDs in
BTRE patients. 
Univariate analysis Odd ratio Multivariate analysis Odd ratio
(p-value) (95% CI) (p-value) (95% CI)
Gender (male vs. female) 0.891 1.21 (0.88-1.50) NA
Age  (≥ 60 yr vs. < 60 yr) 0.743 1.08 (0.77-1.30) NA
KPS score  (≥ 70 vs. < 70) 0.127 1.89 (0.95-2.24) NA
Significance of abnormality in EEG
I vs. II 0.285 1.65 (0.84-1.98) NA
I vs. III 0.024 3.42 (1.21-5.92) 0.017 3.46 (1.35-5.93)
II vs. III 0.050 2.63 (1.77-3.56) 0.048 2.71 (1.85-4.18)
Histopathology of primary cancer
(Non-small cell lung cancers vs. other cancers)
0.341 1.57 (0.88-1.88) NA
Therapeutic modality 
(radiotherapy vs. surgery)
0.524 1.24 (0.74-1.62) NA
Previous history of seizure 
(presence vs. absence)
0.328 1.48 (0.82-2.10) NA
Risk for epileptogenesis 
(high risk vs. low risk)
0.046 2.46 (1.61-3.47) 0.055 2.25 (1.27-3.24)
Disease-progression of brain metastasis
(presence vs. absence)
0.003 4.41 (1.52-6.8) 0.001 4.63 (2.23-7.04)
Table 5. Cox regression analysis for factors affecting seizure-free survival during chemotherapy for systemic cancer with single brain metastasis
CI, confidence interval; NA, not assessed; KPS, Karnofsky Performance Scale; EEG, electroencephalogram.
Seizure history Risk group Disease-progression of BM
Total
Absence Presence Low risk High risk Presence Absence (n=103)
(n=67) (n=36) (n=54) (n=49) (n=24) (n=79)
No. of patients 10 (9.7) 6 (9.0) 4 (11.1) 4 (7.4) 6 (12.2) 9 (37.5)
a) 1 (1.3)
a)
One seizure 2 1 1 1 1 1 1
Two seizures 4 3 1 1 3 4 0
Three seizures 4 1 2 2 2 4 0
Total No. of seizure 24 13 11 10 14 23 1
No. of seizure per patient 0.23 0.19
a) 0.31
a) 0.20 0.26 0.96
a) 0.01
a)  
Timing of first seizure attack (mo)
ģ1 1 1 0 1 0 0 1
1-2 2 0 2 2 0 2 0
2-4 3 1 2 0 3 3 0
ĥ4 4 4 0 1 3 4 0
Type of seizure
Partial seizure 3 2 1 1 2 3 0
Partial seizure with evolving      
2ndary generalization
12 7 5 6 6 11 1
Generalized seizure 9 4 5 3 6 9 0
Table 6. Patterns of brain tumor related epilepsy according to each comparative group during chemotherapy for systemic cancer with single BM
BM, brain metastasis. 
a)Those variables have statistically significant difference (pģ0.05).Cancer Res Treat. 2011;43(3):160-169
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The present study showed that the most important factor to control
BTRE during systemic chemotherapy is disease-progression of BM.
To increase the efficacy of chemotherapy for systemic cancer with
BM, we have to choose drugs with less drug-interaction and less
side effects, which were administered concomitantly during systemic
chemotherapy. Topiramate is a new generation AED that is uniquely
not subject to drug interactions because it is metabolized less by
cytochrome P450, and is less likely to produce side effects than
traditional AEDs [14]. In this study, we gave a prophylactic AED to
the patients who had no previous history of BTRE if they had
abnormal EEG findings. Among 67 patients without a previous
seizure attack, a new BTRE occurred in 6 patients (9.0%). According
to the literature, an epileptic seizure is the clinical presenting sign of
a brain tumor in 30-50% of patients, and an additional 10-30% of
brain tumors patients develop seizures later during the disease
course [1,3,4]. In particular, patients with BM experience seizure in
approximately 25% of patients and 10% of patients complain of
seizures as the initial presenting symptom [3,9]. Despite topiramate
prophylaxis, our study showed that 6 (9.7%) patients developed new
onset BTRE. Furthermore, despite systemic chemotherapy, 5 of 6
patients experienced disease-progression of BM and all had abnormal
EEG signals. In fact, it was thought that because this study was
performed in patients with abnormal findings of EEG, the results
might not show complete prophylaxis for BTRE in patients without
previous BTRE.
Although many studies have been undertaken to determine the
risk of developing BTRE, no comprehensive study has previously
reported that brain tumor progression is a risk factor of BTRE develop-
ment, whereas several studies have found that tumor type and
location are strongly related to BTRE development [11,20]. The
present study presented that BMs with a low threshold of epilepto-
genesis in location have a tendency to develop BTRE more frequently
than those with a high threshold of epileptogensis based on univariate
analysis. However, adjustment for multiple factors presented that
BM located in low threshold of epileptogenesis did not have a
tendency to develop BTRE.
Additionally, our study suggested that the significance of EEG
abnormalities and response to chemotherapy should have an associ-
ation with seizure-free survival. There have been no comprehensive
studies to use EEG during administrating AED in patients with
BMs. Especially, although patients have no history of BTRE, if they
have abnormal finding on EEG, we can consider use of prophylactic
AED in BM patients.
Several studies have been undertaken on new AEDs for BTRE.
Wagner et al. [22] presented preliminary experience for levetiracetam
in patients with a primary brain tumor, after surgery and reported a
seizure-free rate of 20% for 20 patients. However, Wagner et al.
[22] exclusively enrolled patients with primary brain tumors, which
probably accounts for differences from our results because of diffe-
rent types of brain tumors. In a retrospective analysis conducted by
Newton et al. [23], seizure frequency was reduced in 90% of patients
with brain tumors by adding levetiracetam. Newton et al. [23] studied
34 patients with primary brain tumors and 7 metastatic brain tumors,
and concluded that levetiracetam should be considered as add-on
therapy with traditional AEDs or as a substitute anti-convulsant
monotherapy.
Our prospective observational study has many limitations of
defining the incidence and the patterns of BTRE, and a predisposing
factor for BTRE during systemic chemotherapy. First, the histologic
origins of primary tumors were too heterogeneous, thus many factors
in each primary tumor, such as the biology and the chemotherapeutic
agents of each primary tumor, varied. The clinical courses of BM, as
well as the primary tumor, differed. Therefore, our results did not
individualize all of the different conditions in different tumors.
Second, we confined the study period during chemotherapy. We
overlooked the effects of initial treatment of BM, such as radiotherapy
or surgery. Even after chemotherapy for systemic cancer with a
single BM, these therapeutic modalities can influence the development
of BTRE. Third, we could not standardize our results in all BTRE
during chemotherapy for systemic cancer with BM because the
involved chemotherapeutic agents and many other drugs influenced
the development of BTRE. Many medications can cause drug inter-
actions, and thus we cannot account for all possible interactions
between the medications used to treat systemic cancer. Fourth, as
our study showed results in patients with single BM only, we cannot
apply our results to all types of brain tumors. Therefore, a more
comprehensive study is required to resolve this issue.
Conclusion
This prospective observational study suggested that disease pro-
gression of BM and the significance of EEG abnormalities should
have an association with development of BTRE and seizure-free
survival during chemotherapy for systemic cancer with BM. Many
hurdles must be overcome before we are able to control BTRE
during treatment of brain tumors. During concomitant chemotherapy,
drug interactions between AEDs and chemotherapeutics admini-
stered concomitantly are important considerations when choosing
AEDs, as are the intrinsic side effects of AEDs.  Further studies are
warranted to confirm our results and determine the nature of the
interactions between many drugs which are administered con-
comitantly and chemotherapeutics.
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